

EQA round: AIM11/25 - Autoimmunity 1

Deadline: 14.3.2025

Setup: all data

AV = assigned value

N_{tot} = total number of the resultsN_{eva} = number of the results assessed

CVP = consensus of all participants

N_{rel} = relative number of the resultsN_{suc} = number of successful results

>>> ... expected result

S_{rel} = relative success

> ... acceptable result

± ... result not assessed

| Test Sample Group | Frequency of the results | | | | Success | | |
|--|--------------------------|------------------|-------------------------|--|------------------|------------------|-------------------------|
| | AV | N _{tot} | N _{rel} [%] | Result | N _{eva} | N _{suc} | S _{rel} [%] |
| Set 1 | | | | | | | |
| (560) ANA screening (antibodies against cell nucleus) - prove | | 81 | | | 81 | 81 | 100 |
| Sample A1 | | 81 | | | 81 | 81 | 100 |
| All results | CVP >>> | 81 | 100 | Positive | | | |
| Sample B1 | | 81 | | | 81 | 81 | 100 |
| All results | CVP >>> | 81 | 100 | Negative | | | |
| (572) ANA screening (antibodies against cell nucleus) - semi-quantity | | 71 | | | 0 | | |
| Sample A1 | | 71 | | | 0 | | |
| All results | | ± 2 | 2,8 | titre 40 | | | |
| | | ± 2 | 2,8 | titre 80 | | | |
| | | ± 2 | 2,8 | titre 160 | | | |
| | | ± 26 | 37 | titre 320 | | | |
| | | ± 23 | 32 | titre 640 | | | |
| | | ± 12 | 17 | titre 1280 | | | |
| | | ± 4 | 5,6 | titre 2560 | | | |
| Sample B1 | | 71 | | | 0 | | |
| All results | | ± 1 | 1,4 | Not specified | | | |
| | | ± 56 | 79 | titre 0 (not measurable) | | | |
| | | ± 5 | 7 | titre 40 | | | |
| | | ± 8 | 11 | titre 80 | | | |
| | | ± 1 | 1,4 | titre 2560 | | | |
| (561) ANA - type of fluorescence - nucleus | | 74 | | | 74 | 70 | 95 |
| Sample A1 | | 74 | | | 74 | 73 | 99 |
| All results | CVP >>> | 73 | 99 | Fine or coarse speckled or nuclear matrix (AC-4/AC-5) | | | |
| | | 1 | 1,4 | Fine or coarse speckled or nuclear matrix (AC-4/AC-5); DFS 70 (AC-2) | | | |
| Sample B1 | | 74 | | | 74 | 71 | 96 |
| All results | | 3 | 4,1 | Not specified | | | |
| | CVP >>> | 71 | 96 | No fluorescence (AC-0) | | | |
| (563) ANA screening (antibodies against cytoplasm) - prove | | 72 | | | 72 | 71 | 99 |
| Sample A1 | | 72 | | | 72 | 71 | 99 |
| All results | CVP >>> | 71 | 99 | Negative | | | |
| | | 1 | 1,4 | Positive | | | |
| Sample B1 | | 72 | | | 72 | 72 | 100 |
| All results | CVP >>> | 72 | 100 | Negative | | | |
| (573) ANA screening (antibodies against cytoplasm) - semi-quantity | | 68 | | | 0 | | |
| Sample A1 | | 68 | | | 0 | | |
| All results | | ± 53 | 78 | titre 0 (not measurable) | | | |
| | | ± 5 | 7,4 | titre 40 | | | |
| | | ± 8 | 12 | titre 80 | | | |
| | | ± 1 | 1,5 | titre 640 | | | |
| | | ± 1 | 1,5 | titre 2560 | | | |
| Sample B1 | | 68 | | | 0 | | |
| All results | | ± 54 | 79 | titre 0 (not measurable) | | | |
| | | ± 5 | 7,4 | titre 40 | | | |
| | | ± 8 | 12 | titre 80 | | | |
| | | ± 1 | 1,5 | titre 2560 | | | |
| (564) ANA - type of fluorescence - cytoplasm | | 69 | | | 69 | 68 | 99 |
| Sample A1 | | 69 | | | 69 | 68 | 99 |
| All results | CVP >>> | 68 | 99 | No fluorescence (AC-0) | | | |
| | | 1 | 1,4 | Dense or fine speckled cytoplasm (AC-19/AC-20) | | | |
| Sample B1 | | 69 | | | 69 | 69 | 100 |
| All results | CVP >>> | 69 | 100 | No fluorescence (AC-0) | | | |
| Set 2 | | | | | | | |
| (585) anti-centromere | | 75 | | | 75 | 75 | 100 |
| Sample A2 | | 75 | | | 75 | 75 | 100 |
| All results | CVP >>> | 75 | 100 | Negative | | | |
| Sample B2 | | 75 | | | 75 | 75 | 100 |
| All results | CVP >>> | 75 | 100 | Negative | | | |

EQA round: AIM11/25 - Autoimmunity 1

Deadline: 14.3.2025

Setup: all data

| Test Sample Group | AV | N _{tot} | Frequency of the results | | | Success | | |
|--|---------|------------------|--------------------------|----------------------------------|------------------|------------------|-------------------------|-----|
| | | | N _{rel} [%] | Result | N _{eva} | N _{suc} | S _{rel} [%] | |
| (584) anti-ENA, antigen Jo-1 | | 78 | | | | 78 | 77 | 99 |
| Sample A2 | | 78 | | | | 78 | 77 | 99 |
| All results | CVP >>> | 77 | 99 | Negative | | | | |
| | | 1 | 1,3 | Inconclusive result (borderline) | | | | |
| Sample B2 | | 78 | | | | 78 | 78 | 100 |
| All results | CVP >>> | 78 | 100 | Negative | | | | |
| (583) anti-ENA, antigen RNP | | 78 | | | | 78 | 67 | 86 |
| Sample A2 | | 78 | | | | 78 | 68 | 87 |
| All results | | 9 | 12 | Negative | | | | |
| | | 1 | 1,3 | Inconclusive result (borderline) | | | | |
| | CVP >>> | 68 | 87 | Positive | | | | |
| Sample B2 | | 78 | | | | 78 | 77 | 99 |
| All results | CVP >>> | 77 | 99 | Negative | | | | |
| | | 1 | 1,3 | Positive | | | | |
| (582) anti-ENA, antigen Scl-70 | | 78 | | | | 78 | 78 | 100 |
| Sample A2 | | 78 | | | | 78 | 78 | 100 |
| All results | CVP >>> | 78 | 100 | Negative | | | | |
| Sample B2 | | 78 | | | | 78 | 78 | 100 |
| All results | CVP >>> | 78 | 100 | Negative | | | | |
| (580) anti-ENA, antigen SS-A/Ro-60 | | 78 | | | | 78 | 78 | 100 |
| Sample A2 | | 78 | | | | 78 | 78 | 100 |
| All results | CVP >>> | 78 | 100 | Positive | | | | |
| Sample B2 | | 78 | | | | 78 | 78 | 100 |
| All results | CVP >>> | 78 | 100 | Negative | | | | |
| (581) anti-ENA, antigen SS-B/La | | 78 | | | | 78 | 78 | 100 |
| Sample A2 | | 78 | | | | 78 | 78 | 100 |
| All results | CVP >>> | 78 | 100 | Positive | | | | |
| Sample B2 | | 78 | | | | 78 | 78 | 100 |
| All results | CVP >>> | 78 | 100 | Negative | | | | |
| Set 3 | | | | | | | | |
| (588) anti-dsDNA immunofluorescence - prove | | 56 | | | | 56 | 54 | 96 |
| Sample A3 | | 56 | | | | 56 | 55 | 98 |
| All results | CVP >>> | 55 | 98 | Negative | | | | |
| | | 1 | 1,8 | Positive | | | | |
| Sample B3 | | 56 | | | | 56 | 54 | 96 |
| All results | | 2 | 3,6 | Negative | | | | |
| | CVP >>> | 54 | 96 | Positive | | | | |
| (577) anti-dsDNA immunofluorescence - semi-quantity | | 52 | | | | 0 | | |
| Sample A3 | | 52 | | | | 0 | | |
| All results | | ± 1 | 1,9 | Not specified | | | | |
| | | ± 44 | 85 | titre 0 (not measurable) | | | | |
| | | ± 6 | 12 | titre 10 | | | | |
| | | ± 1 | 1,9 | titre 2560 | | | | |
| Sample B3 | | 52 | | | | 0 | | |
| All results | | ± 2 | 3,8 | titre 10 | | | | |
| | | ± 3 | 5,8 | titre 20 | | | | |
| | | ± 2 | 3,8 | titre 40 | | | | |
| | | ± 16 | 31 | titre 80 | | | | |
| | | ± 11 | 21 | titre 160 | | | | |
| | | ± 13 | 25 | titre 320 | | | | |
| | | ± 4 | 7,7 | titre 640 | | | | |
| | | ± 1 | 1,9 | titre 2560 | | | | |
| (589) anti-dsDNA other methods | | 61 | | | | 61 | 56 | 92 |
| Sample A3 | | 61 | | | | 61 | 58 | 95 |
| All results | CVP >>> | 58 | 95 | Negative | | | | |
| | | 2 | 3,3 | Inconclusive result (borderline) | | | | |
| | | 1 | 1,6 | Positive | | | | |
| Sample B3 | | 61 | | | | 61 | 59 | 97 |
| All results | | 2 | 3,3 | Negative | | | | |
| | CVP >>> | 59 | 97 | Positive | | | | |
| Set 4 | | | | | | | | |
| (591) anti-nukleosoms IgG | | 55 | | | | 55 | 55 | 100 |
| Sample A4 | | 55 | | | | 55 | 55 | 100 |
| All results | CVP >>> | 55 | 100 | Negative | | | | |
| Sample B4 | | 55 | | | | 55 | 55 | 100 |
| All results | CVP >>> | 55 | 100 | Positive | | | | |